Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23522143 | 1.00 | KDM4E (0.33) | KDM4EALDH1A1LMNAGAATSHR | |
| SCHEMBL21724755 | 1.00 | KDM4E (0.33) | KDM4EALDH1A1LMNAGAATSHR | |
| SCHEMBL23522141 | 1.00 | KDM4E (0.33) | KDM4EALDH1A1LMNAGAATSHR | |
| SCHEMBL31611279 | 0.88 | KDM4E (0.35) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL23522183 | 0.84 | NFE2L2 (0.38) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL23522213 | 0.84 | NFE2L2 (0.38) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL23522211 | 0.84 | NFE2L2 (0.38) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL23522180 | 0.84 | NFE2L2 (0.38) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL23522182 | 0.84 | NFE2L2 (0.38) | KDM4EALDH1A1LMNAGAAHPGD | |
| SCHEMBL29838644 | 0.84 | NFE2L2 (0.38) | KDM4EALDH1A1LMNAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976059-B2 | Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-05-07 | — | — | US | disclosed |
| CN-112839937-B | Isoindolin-1-one derivatives, preparation method and application thereof | 韩国化学研究院 | 2023-08-22 | — | — | CN | disclosed |
| EP-3838898-B1 | ISOINDOLIN-1-ONE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS AN EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | KOREA RES INST CHEMICAL TECH (KR) | 2023-06-07 | — | — | EP | disclosed |
| US-20210332029-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-10-28 | — | — | US | disclosed |
| EP-3838898-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | Korea Research Institute of Chemical Technology (KR) | 2021-06-23 | — | — | EP | disclosed |
| CN-112839937-A | Isoindolin-1-one derivative, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as effective component | 韩国化学研究院 | 2021-05-25 | — | — | CN | disclosed |
| WO-2020036386-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | 한국화학연구원 | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332029-A1 | ISOINDOLIN-1-ON DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING CANCER | EGFR, TP53, BRCA1 | KDM4E 4462/4885ALDH1A1 1073/4885LMNA 3617/4885 |
| US-11976059-B2 | Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancer | EGFR, TP53, BRCA1 | KDM4E 4462/4885ALDH1A1 1073/4885LMNA 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.